The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients

Danish Headache Center

Status

Completed

Conditions

Headache, Migraine

Treatments

Drug: Maxipost

Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

NCT03887325

Maxipost P H-18052101

Details and patient eligibility

About

It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology.

Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated.

The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.

Enrollment

43 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Migraine patients without aura who fulfill criteria in the international classification of headaches. This does not apply to healthy volunteers.
18-60 years.
50-90 kg.
Women of childbearing potential must use adequate contraception.

Exclusion criteria

Headache less than 48 hours before the tests start
All primary headaches, except migraine without aura for migraine patients, according to international classification of headache
Daily consumption of drugs of any kind other than oral contraceptives
Pregnant or nursing women.
Cardiovascular disease of any kind, including cerebrovascular diseases.